Latigo Biotherapeutics, Inc. LTGO
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Net Income | 0.15% | -9.59% | |||
| Total Depreciation and Amortization | -21.21% | -29.85% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | -14.85% | 39.02% | |||
| Change in Net Operating Assets | 25.18% | -250.73% | |||
| Cash from Operations | 1.29% | -27.94% | |||
| Capital Expenditure | -233.33% | -- | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | -- | |||
| Cash from Investing | -233.33% | -- | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -- | |||
| Cash from Financing | 3,418,000.00% | -100.23% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 159.22% | -134.92% | |||